LMR Partners
RLMD icon

LMR Partners’s Relmada Therapeutics RLMD Stock Holding History

LMR Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
55,600
-7,984
-13% -$55.8K ﹤0.01% 1221
2026
Q1 		$443K Buy
63,584
+7,984
+14% +$37.8K ﹤0.01% 1099
2025
Q4 		$269K Hold
55,600
– – ﹤0.01% 1231
2025
Q3 		$112K Buy
55,600
+496
+0.9% +$476 ﹤0.01% 1274
2025
Q2 		$33.1K Buy
+55,104
New +$28.3K ﹤0.01% 1237

Other funds holding RLMD

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LMR Partners's RLMD Position: Q2 2026 in Review

LMR Partners reduced its Relmada Therapeutics (RLMD) stake by 13% in Q2 2026, selling an estimated $55.8K and leaving 55,600 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

LMR Partners first reported a position in RLMD in Q2 2025 and has held it in 5 quarters since. The position peaked at $443K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • LMR Partners held 55,600 shares of Relmada Therapeutics worth $385K as of Q2 2026.
  • LMR Partners sold 7,984 Relmada Therapeutics shares in Q2 2026, an estimated $55.8K.
  • Relmada Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1221 holding.
  • LMR Partners first reported a position in Relmada Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • LMR Partners's Relmada Therapeutics position peaked at $443K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.